Asset profile
Mevidalen
Small molecule
Evidence outlook · results not reported
NCT06538116 · Alzheimer Disease
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06538116: The trial randomized 304 participants to two mevidalen dose groups or placebo and used double blinding of participants and investigators. Its primary clinical cognitive-and-functional endpoint was specified, but results and statistical comparisons are not yet available.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 31 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mevidalen: this drug | Phase 2 | Small molecule | Dopamine D1 receptor | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | ||
| AR1001 | Phase 3 | Small molecule | PDE5 | ||
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | ||
| Blarcamesine | Phase 3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | ||
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | ||
| Cerebrolysin | Phase 3 | Peptide | Multi-target (ginsenoside) | ||
| GV1001 | Phase 3 | Peptide | Telomerase (hTERT) | ||
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | ||
| Lemborexant (Dayvigo) | Phase 3 | Small molecule | Orexin receptor (repositioned) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.